VK2735

DRUG5 trials

Sponsors

Viking Therapeutics, Inc.

Conditions

NASHWeight Loss

Phase 1

Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

CompletedNCT05203237

Viking Therapeutics, Inc.NASH, Weight Loss

Start: 2021-12-14End: 2024-12-03Updated: 2025-02-17

Phase 2

VK2735 for Weight Management Phase 2

CompletedNCT06068946

Viking Therapeutics, Inc.Weight Loss

Start: 2023-08-31End: 2024-04-02Updated: 2025-02-12

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

CompletedNCT06828055

Viking Therapeutics, Inc.Weight Loss

Start: 2024-12-18End: 2025-08-15Updated: 2025-10-06

Phase 3

VK2735 for Weight Management Phase 3

Active, not recruitingNCT07104500

Viking Therapeutics, Inc.Weight Loss

Start: 2025-06-23End: 2027-08-01Target: 4500Updated: 2025-11-24

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Active, not recruitingNCT07104383

Viking Therapeutics, Inc.Weight Loss

Start: 2025-06-23End: 2027-08-01Target: 1100Updated: 2026-04-07

Related Papers

Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.

2026-01-08